BioCentury
ARTICLE | Clinical News

ArQule begins Phase I of ARQ 531 in B cell malignancies

August 17, 2017 11:45 PM UTC

ArQule Inc. (NASDAQ:ARQL) began a Phase I trial to evaluate once-daily oral ARQ 531 for 4 weeks in patients with relapsed or refractory B cell malignancies.

The trial's dose-escalation first portion will test ARQ 531 at a starting dose of 5 mg to determine a recommended Phase II dose. The second portion will evaluate that dose in expansion cohorts for specific malignancies, including a cohort of patients with the C481S Bruton’s tyrosine kinase (Btk) mutation. ArQule expects to enroll up to 120 patients overall...

BCIQ Company Profiles

ArQule Inc.

BCIQ Target Profiles

Bruton's tyrosine kinase (Btk)